A Kaplan–Meier analysis of GBM patients, stratified by methylation load and mRNA expression (Figure 5B–D), demonstrated a statistically significant enhancement in survival durations for the patients predicting elevated levels of HIF1A, TRIM22, and PARP9 mRNA, coupled with a high methylation load (sum of beta values for TGFB1/2/3 and MGMT). This evidence concerns the gene MGMT and glioblastoma.